Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.

Abstract

Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas.Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission with belinostat for 39 months.

• Authors: Peter Reimer, Shanta Chawla
• Journal: Journal of hematology & oncology (J Hematol Oncol) Vol. 6 Pg. 69 (Sep 10 2013) ISSN: 1756-8722 [Electronic] England
• PMID: 24020452 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Hydroxamic Acids
• Sulfonamides
• belinostat

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Female
• Humans
• Hydroxamic Acids (therapeutic use)
• Lymphoma, T-Cell, Peripheral (drug therapy)
• Prognosis
• Remission Induction
• Sulfonamides (therapeutic use)